Malaysia. The Drug Control Authority (DCA) in Malaysia has directed the manufacturer of tirofiban (Aggrastat) to issue a ‘Dear Doctor’ letter advising health professionals against the off-label usage of tirofiban (Aggrastat) injection. This advice follows reports of fatal outcomes occurring with the use of tirofiban with heparin during cardiopulmonary bypass in patients who previously experienced heparin-induced thrombocytopenia type II reactions.

Reference:

Malaysian News. Available from URL: http://www.bpfk.gov.my